NCT02639351View on ClinicalTrials.gov

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R

Intramuscular (IM) vaccination of 1 dose of 0.5 mL

BIOLOGICAL

Investigational MenC-CRM adjuavnted with 25 ug of LHD153R

IM vaccination of 1 dose of 0.5 mL

BIOLOGICAL

Investigational MenC-CRM adjuavnted with 50 ug of LHD153R

IM vaccination of 1 dose of 0.5 mL

BIOLOGICAL

Investigational MenC-CRM adjuavnted with 100 ug of LHD153R

IM vaccination of 1 dose of 0.5 mL

BIOLOGICAL

Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

IM vaccination of 1 dose of 0.5 mL

Trial Locations (1)

14050

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02639351 - Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine | Biotech Hunter | Biotech Hunter